On this page
B4GALT1
beta-1,4-galactosyltransferase 1
B4GALT1 is located on the short (p) arm of chromosome 9, at band 9p21.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 9 in the library →Available at Jeen Health
Clinical tests that include this
Overview
B4GALT1 is located on chromosome 9 at position 9p21.1 and encodes a glycosyltransferase enzyme responsible for attaching galactose residues to glycoproteins and glycolipids. The gene follows an autosomal recessive inheritance pattern, meaning that both copies must carry pathogenic variants for disease to manifest.
Glycosylation - the addition of sugar molecules to proteins and fats - is essential for cellular recognition, immune function, and maintaining the structural integrity of tissues. The enzyme produced by B4GALT1 catalyses a specific step in this process, forming beta-1,4 linkages between galactose and N-acetylglucosamine residues. Disruption of this activity can lead to congenital disorders of glycosylation, a group of inherited metabolic conditions affecting multiple organ systems.
What the gene does
The B4GALT1 protein functions as a Golgi-resident enzyme that catalyses the transfer of galactose from UDP-galactose donor molecules to acceptor substrates containing N-acetylglucosamine. This reaction is a key step in the biosynthesis of complex N-glycans and glycolipids, which decorate the surface of cells and secreted proteins.
The enzyme plays a particularly important role in synthesising lactose in mammary tissue during lactation, where it forms a complex with alpha-lactalbumin to alter substrate specificity. Beyond lactose production, B4GALT1 contributes to the maturation of glycan structures on immunoglobulins, cell-surface receptors, and extracellular matrix components. These sugar modifications influence protein folding, stability, trafficking, and interactions with other molecules, thereby affecting processes ranging from immune recognition to cell adhesion and signal transduction across diverse tissues.
Video: Genetics 101
Chromosome location
B4GALT1 is positioned on the short arm of chromosome 9 at cytogenetic band 9p21.1. This chromosomal region contains several genes involved in metabolic and regulatory processes. The genomic structure and exon organisation of B4GALT1 support the production of a 398-amino-acid protein that localises primarily to the Golgi apparatus, the cellular compartment where most glycosylation reactions occur.
Protein structure
The B4GALT1 protein comprises 398 amino acids and contains a disordered region spanning amino acids 61-117. Disordered regions lack a fixed three-dimensional structure and often participate in regulatory interactions or provide flexibility for conformational changes during catalysis. The enzyme's catalytic domain is responsible for binding both the sugar donor and acceptor substrates, whilst the N-terminal portion includes sequences that anchor the protein to Golgi membranes, ensuring it remains in the correct cellular compartment to perform its glycosylation functions.
Key variants
Pathogenic variants in B4GALT1 typically impair the enzyme's ability to transfer galactose efficiently, leading to incomplete glycosylation of cellular proteins and lipids. Missense variants that alter critical amino acids in the catalytic domain are common mechanisms of disease, though loss-of-function variants affecting protein stability or expression have also been reported. The severity of clinical manifestations often correlates with the degree of residual enzyme activity.
Sample of pathogenic variants
3 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1031dup | p.Arg345fs | Pathogenic | - | B4GALT1-congenital disorder of glycosylation |
c.1055A>G | p.Asn352Ser | Pathogenic | - | Combined low LDL and fibrinogen |
c.579C>G | p.Tyr193Ter | Pathogenic | - | B4GALT1-congenital disorder of glycosylation |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in B4GALT1 cause a congenital disorder of glycosylation, which presents with a spectrum of symptoms affecting the nervous system, muscles, and connective tissues. Individuals with this condition may experience developmental delay, muscle weakness, movement disorders, and skeletal abnormalities due to the widespread disruption of glycoprotein and glycolipid function. The condition is classified within the broader category of metabolic disorders that affect post-translational modification of proteins, and clinical severity can vary depending on the specific variants inherited.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic B4GALT1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
B4GALT1 is included on several NHS Genomic Medicine Service gene panels with a 'green' classification, indicating strong evidence for its clinical validity. The gene appears on the Congenital Disorders of Glycosylation panel, the DDG2P (Developmental Disorders Genotype-to-Phenotype) panel, the Likely Inborn Error of Metabolism panel (assigned code R98), and the Undiagnosed Metabolic Disorders panel. This multi-panel presence reflects the gene's established role in glycosylation defects and supports its use in diagnostic testing pathways for individuals with unexplained metabolic or developmental presentations.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does autosomal recessive inheritance mean for B4GALT1?
Autosomal recessive inheritance means that an individual must inherit a pathogenic variant in both copies of the B4GALT1 gene (one from each parent) to develop a related condition. Carriers, who have only one pathogenic variant, typically do not show symptoms but can pass the variant to their children.
How does B4GALT1 relate to lactose production?
In mammary tissue, the B4GALT1 enzyme interacts with alpha-lactalbumin to form lactose synthase, which produces lactose - the primary sugar in human milk. Outside of lactation, the enzyme focuses on glycosylating proteins and lipids rather than producing free lactose.
Why is B4GALT1 on multiple NHS gene panels?
B4GALT1 appears on multiple NHS panels because glycosylation defects can present with diverse clinical features affecting development, metabolism, and multiple organ systems. The gene's inclusion on congenital disorder of glycosylation, metabolic, and developmental panels reflects the broad spectrum of symptoms that can arise from impaired galactosyltransferase activity.